Brainstorm Cell Therapeutics(BCLI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BCLI Brainstorm Cell Therapeutics

Trading 04-02 12:08:02 EDT

1.24

+0.05

+4.20%

High1.24	Low1.16	Vol8.19K
Open1.18	D1 Closing1.19	Amplitude6.72%
Mkt Cap8.09M	Tradable Cap6.51M	Total Shares6.52M
T/O9.90K	T/O Rate0.16%	Tradable Shares5.25M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"BCLI","market":"US","secType":"STK","nameCN":"Brainstorm Cell Therapeutics","latestPrice":1.24,"timestamp":1743609708482,"preClose":1.19,"halted":0,"volume":8187,"delay":0,"floatShares":5249800,"shares":6522400,"eps":-3.203247,"marketStatus":"Trading","change":0.05,"latestTime":"04-02 12:08:02 EDT","open":1.18,"high":1.24,"low":1.16,"amount":9904.4303811,"amplitude":0.067227,"askPrice":1.23,"askSize":74,"bidPrice":1.16,"bidSize":157,"shortable":3,"etf":0,"ttmEps":-3.203247,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1743624000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1052452800000,"exchange":"NASDAQ","adjPreClose":1.19,"preHourTrading":{"tag":"盘前","latestPrice":1.19,"preClose":1.19,"latestTime":"08:29 EDT","volume":17,"amount":20.23,"timestamp":1743596978271},"postHourTrading":{"tag":"盘后","latestPrice":1.19,"preClose":1.19,"latestTime":"16:54 EDT","volume":4,"amount":5.04,"timestamp":1743540859102},"volumeRatio":0.411708,"impliedVol":0.6467,"impliedVolPercentile":0.4206},"requestUrl":"/m/hq/s/BCLI","defaultTab":"news","newsList":[{"id":"2524259151","title":"Brainstorm Cell Therapeutics Inc (BCLI) Q4 2024 Earnings Call Highlights: Navigating Financial ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2524259151","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524259151?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 15:01","pubTimestamp":1743490872,"startTime":"0","endTime":"0","summary":"Research and Development Expenditures: $4.7 million for the year ended December 31, 2024, compared to $10.7 million in 2023.Net Loss: Approximately $11.6 million or $2.31 per share for the year ended December 31, 2024, compared to $17.2 million or $6 per share in 2023.Cash, Cash Equivalents, and Restricted Cash: Approximately $0.4 million as of December 31, 2024, compared to $1.5 million as of December 31, 2023.Warrant Inducement Agreement: Expected to raise approximately $1.64 million in gross proceeds, closing on or about April 1, 2025.GuruFocus has detected 2 Warning Signs with BCLI.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Brainstorm Cell Therapeutics Inc  has secured a special protocol assessment with the FDA, significantly de-risking the regulatory pathway for their NurOwn technology.The company has contracted with Pluri Inc. for clinical manufacturing, leveraging their expertise in GMP-compliant production, and plans to b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/brainstorm-cell-therapeutics-inc-bcli-070112436.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCLI"],"gpt_icon":0},{"id":"2524139479","title":"Q4 2024 Brainstorm Cell Therapeutics Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2524139479","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524139479?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 11:41","pubTimestamp":1743478888,"startTime":"0","endTime":"0","summary":"Chaim Lebovits; President, Chief Executive Officer; Brainstorm Cell Therapeutics Inc. Alla Patlis; Interim Chief Financial Officer, Controller; Brainstorm Cell Therapeutics Inc. Bob Dagher; Executive Vice President, Chief Development Officer; Brainstorm Cell Therapeutics Inc. Haro Hartounian; Executive Vice President & Chief Operating Officer; Brainstorm Cell Therapeutics Inc. Good morning, everyone, and welcome to BrainStorm Cell Therapeutics' fourth-quarter 2024 earnings call.  Please note this conference is being recorded. I will now turn the conference over to your host, Michael Wood. Michael, the floor is yours.Thank you, Michael. Good morning, good afternoon to everyone. Thank you for joining us today. We appreciate your continued interest and support in BrainStorm. 2024 was a year of foundational work, positioning us for the critical Phase 3b trial of NurOwn, our investigational treatment for ALS. Our team, in close collaboration with leading ALS experts and regulatory authoriti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-brainstorm-cell-therapeutics-034128631.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCLI"],"gpt_icon":0},{"id":"2523422419","title":"Brainstorm Cell Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2523422419","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523422419?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 21:32","pubTimestamp":1743427925,"startTime":"0","endTime":"0","summary":"Brainstorm Cell Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryBrainstorm Cell Therapeutics Inc BCLI.OQ reported a quarterly adjusted loss of 51 cents per share f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nL5N3QE101:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCLI"],"gpt_icon":0},{"id":"2523917894","title":"Press Release: BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2523917894","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523917894?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 19:00","pubTimestamp":1743418800,"startTime":"0","endTime":"0","summary":"Conference call and webcast at 8:30 a.m. Eastern Time today. NEW YORK, March 31, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2024, and provided a corporate update.-- December 30, 2024: Issued a letter to shareholders summarizing key. -- December 11, 2024: Hosted a key opinion leader  webinar featuring. Dr. Terry Heiman-Patterson, from the Lewis Katz School of Medicine. at Temple University. Dr. Heiman-Patterson discussed the current. treatment landscape and advances for patients with ALS . The replay. can be accessed on the corporate website here.-- November 11, 2024: Announced a strategic partnership with Pluri to. support manufacturing for the Phase 3b NurOwn trial, enhancing. -- October 30, 2024: Regained compliance with Nasdaq's minimum bid price. requirement, maintaining continued listing on the Nasdaq Capital Mar","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0106831901.USD","LU1668664300.SGD","LU1720051017.SGD","LENZ","IE00BZ1G4Q59.USD","LU0912757837.SGD","LU0314104364.USD","LU0149725797.USD","IE00BHPRN162.USD","LU0795875086.SGD","LU2347655156.SGD","LU0158827948.USD","LU0267386448.USD","IE00B1BXHZ80.USD","LU1162221912.USD","LU2271345857.HKD","CMC","KOL","LU1732800096.USD","LU2028103732.USD","LU0795875169.SGD","BK4581","LU0106261372.USD","LU0320765646.SGD","LU2023251221.USD","LU1548497426.USD","LU2089283258.USD","LU2111349929.HKD","LU1989772923.USD","LU2089284900.SGD","LU1720051108.HKD","LU2133065610.SGD","BK4516","LU1363072403.SGD","BK4585","LU0098860793.USD","BK4534","R","BK4022","LU1989772840.SGD","LU1732799900.SGD","LU2357305700.SGD","BK4127","BK4006","LU0971096721.USD","BK4504","BCLI","LU0158827781.USD","BK4232","BK4588"],"gpt_icon":0},{"id":"2522571804","title":"Brainstorm Cell Therapeutics Inc  expected to post a loss of 38 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2522571804","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522571804?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 20:51","pubTimestamp":1743166268,"startTime":"0","endTime":"0","summary":"Brainstorm Cell Therapeutics Inc  expected to post a loss of38cents a share - Earnings Preview Brainstorm Cell Therapeutics Inc BCLI.OQ BCLI.O is expected to show no change in quarterly revenue when i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL5N3QB0ZC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCLI"],"gpt_icon":0},{"id":"2522872750","title":"Brainstorm Cell Therapeutics Granted Compliance Extension From Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2522872750","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522872750?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 20:15","pubTimestamp":1742991303,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA2X7PLT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCLI","BK4139"],"gpt_icon":0},{"id":"2522387752","title":"BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2522387752","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522387752?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 20:15","pubTimestamp":1742991300,"startTime":"0","endTime":"0","summary":"NEW YORK, March 26, 2025 /PRNewswire/ --BrainStorm Cell Therapeutics Inc. , a leading biotechnology company committed to the development and commercialization of best-in-class autologous cellular therapies for the treatment of neurodegenerative diseases, today announced that it has been granted the exact compliance extension it requested from the Nasdaq Hearings Panel through June 30, 2025, to regain compliance with certain continued listing standards of The Nasdaq Capital Market.BrainStorm presented its request for continued listing on The Nasdaq Capital Market and the relevant compliance plan to the Nasdaq Hearings Panel at the panel hearing held on February 25, 2025. As a result of the hearing, the Nasdaq Hearings Panel granted BrainStorm an extension until June 30, 2025 to regain compliance with certain continued listing standards. The grant of such exception reflects BrainStorm's commitment to executing its compliance plan to meet the applicable requirements within the specified t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/brainstorm-cell-therapeutics-granted-compliance-121500407.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/brainstorm-cell-therapeutics-granted-compliance-121500407.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1548497426.USD","NDAQ","LU0106261372.USD","LU2133065610.SGD","IE00BZ1G4Q59.USD","LU2347655156.SGD","LU0106831901.USD","LU1720051108.HKD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","USJW.SI","LU2357305700.SGD","LENZ","BCLI","QQQ","LU0795875169.SGD","LU2095319765.USD","TSYW.SI","BK4534",".IXIC","LU1989772840.SGD","LU2271345857.HKD","NVIW.SI","LU2210149790.SGD","QLD","BK4588","BK4127","BK4504","MNQmain","LU1732800096.USD","LU1074936037.SGD","QID","USAW.SI","NQmain","PSQ","LU0314104364.USD","LU0098860793.USD","LU1720051017.SGD","LU2089284900.SGD","LU0912757837.SGD","LU1363072403.SGD","LU0006306889.USD","LU2210150020.SGD","BK4139","LU1668664300.SGD","SQQQ","LU0267386448.USD","LU1162221912.USD","TQQQ","LU0795875086.SGD"],"gpt_icon":0},{"id":"2521745269","title":"Brainstorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2521745269","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521745269?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 19:00","pubTimestamp":1742814008,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nTUA4GMRVV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCLI"],"gpt_icon":0},{"id":"2521741887","title":"BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2521741887","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521741887?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 19:00","pubTimestamp":1742814000,"startTime":"0","endTime":"0","summary":"Call Scheduled for March 31, 2025, at 8:30 AM Eastern Time. NEW YORK, March 24, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a conference call and webcast to update shareholders on financial results for the fourth quarter and year ended December 31, 2024, at 8.30 a.m. Eastern Time on March 31, 2025.BrainStorm's President and Chief Executive Officer, Chaim Lebovits, will provide the update. Hartoun Hartounian, PhD, Chief Operating Officer, and Bob Dagher, MD, Chief Medical Officer, and Alla Patlis, interim Chief Financial Officer, will also participate in the call. Following the prepared remarks, there will be a Q&A session with the investment community.The investment community may participate in the conference call by dialing the following numbers:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/brainstorm-announce-fourth-quarter-fiscal-110000963.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/brainstorm-announce-fourth-quarter-fiscal-110000963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4534","LU1720051108.HKD","LU0912757837.SGD","LU2111349929.HKD","LU0320765646.SGD","LU0314104364.USD","LU1989772840.SGD","LU1548497426.USD","BK4588","BK4516","BK4127","LU0098860793.USD","LU0158827781.USD","LU0158827948.USD","LU1732800096.USD","BK4585","LU0971096721.USD","IE00BKVL7J92.USD","LU1668664300.SGD","LU2089283258.USD","LU2347655156.SGD","LU0106831901.USD","LU2089284900.SGD","LU0006306889.USD","LU0106261372.USD","LU1074936037.SGD","LU0795875086.SGD","BCLI","LU2028103732.USD","BK4504","IE00BZ1G4Q59.USD","LU0267386448.USD","LU1720051017.SGD","LU1732799900.SGD","LU1363072403.SGD","LU1989772923.USD","LU2023251221.USD","LU0795875169.SGD","LU2133065610.SGD","BK4581","BK4139","LU2357305700.SGD","LU1162221912.USD","LU2271345857.HKD","LU0225283273.USD"],"gpt_icon":0},{"id":"2501257550","title":"BCLI: Plans Coming Together for Phase 3b Trial of NurOwn® in ALS…","url":"https://stock-news.laohu8.com/highlight/detail?id=2501257550","media":"Zacks Small Cap Research","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501257550?lang=en_us&edition=full_marsco","pubTime":"2025-01-06 18:05","pubTimestamp":1736157900,"startTime":"0","endTime":"0","summary":"On December 30, 2024, BrainStorm Cell Therapeutics, Inc.  conducted an investor update call to provide a corporate update. The company is currently preparing for a Phase 3b clinical trial of NurOwn in patients with amyotrophic lateral sclerosis . During 2024, the company achieved a number of significant milestones in support of the upcoming Phase 3b trial:. In April 2024, the company announced it had received written agreement from the U.S. Food and Drug Administration  under a Special Protocol Assessment  on the design of the Phase 3b trial. The SPA agreement indicates that the FDA concurs with the adequacy and acceptability of specific elements of a protocol’s overall design to ensure that the trial conducted under the protocol can be considered an adequate and well-controlled study to support marketing approval.At the final visit in the EAP, 9/10 participants were alive. A comparison of the survival curves showed","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bcli-plans-coming-together-phase-100500419.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0170899867.USD","LU0971096721.USD","BK4006","PSM","BCLI","CMC","IE00BHPRN162.USD","LU0267386448.USD","BK4139","IE00BKVL7J92.USD","LU0882574139.USD","LU1363072403.SGD","SPA","IE00BZ1G4Q59.USD","LU0149725797.USD","IE00B1BXHZ80.USD"],"gpt_icon":1},{"id":"2495427065","title":"BrainStorm Issues 2024 Letter to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2495427065","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495427065?lang=en_us&edition=full_marsco","pubTime":"2024-12-30 21:00","pubTimestamp":1735563600,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec. 30, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to shareholders.2024 has been a very productive year for BrainStorm Cell Therapeutics, defined by remarkable milestones and achievements that have brought us closer to our mission of delivering groundbreaking therapies for neurodegenerative diseases. I am proud to share this summary of our accomplishments as we close the year with optimism and look forward to the promise of 2025.These results are particularly meaningful because they provide a quantifiable measure of NurOwn's biological impact, complementing clinical assessments of patient function and quality of life. Beyond NfL, exploratory analyses have highlighted potential correlations between NurOwn treatment and other biomarkers associated with inflammation and neuroprotection, further emphasizing the potential multifaceted benefits of our therapy. To","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/brainstorm-issues-2024-letter-shareholders-130000183.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/brainstorm-issues-2024-letter-shareholders-130000183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MSC","LU1363072403.SGD","BK4006","BK4575","LU0170899867.USD","LU0267386448.USD","BK4150","IE00BHPRN162.USD","SPA","LU0149725797.USD","CMC","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4139","LU0882574139.USD","LU0971096721.USD","IE00B1BXHZ80.USD","BCLI"],"gpt_icon":0},{"id":"2491179579","title":"Analysts Offer Insights on Healthcare Companies: Opus Genetics (IRD) and Brainstorm Cell Therapeutics (BCLI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2491179579","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491179579?lang=en_us&edition=full_marsco","pubTime":"2024-12-15 23:50","pubTimestamp":1734277821,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Opus Genetics (IRD – Research Report) and Brainstorm...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-opus-genetics-ird-and-brainstorm-cell-therapeutics-bcli?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-opus-genetics-ird-and-brainstorm-cell-therapeutics-bcli?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IRD","BK4137","HCSG","BCLI","BK4139","BK4007"],"gpt_icon":0},{"id":"2490672544","title":"Brainstorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2490672544","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490672544?lang=en_us&edition=full_marsco","pubTime":"2024-12-09 20:00","pubTimestamp":1733745604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nTUA9TXXZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCLI"],"gpt_icon":0},{"id":"2490229357","title":"BrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2490229357","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490229357?lang=en_us&edition=full_marsco","pubTime":"2024-12-09 20:00","pubTimestamp":1733745600,"startTime":"0","endTime":"0","summary":"Call Scheduled for December 30, 2024, at 8:30 AM ET; Additionally, Key Opinion Leader Webinar on ALS Advancements to Take Place on December 11, 2024. NEW YORK, Dec. 9, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today thatit will hold a conference call and webcast on December 30, 2024, at 8:30 a.m. Eastern Time.AboutBrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative therapies for debilitating neurodegenerative diseases, leveraging both autologous and allogeneic platforms. The Company holds exclusive worldwide licensing rights for the NurOwn technology platform, which produces autologous MSC-NTF cells. These cells have received Orphan Drug designation from the U.S. Food and Drug Administration  and the European Medicines Agency  for amyotrophic lateral sclerosis . BrainStorm is currently planning the launch of a confirmatory Pha","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OOkutZzmduEoM.09cK39MQ--~B/aD0xMzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c3251351433584be7e825803dfe4a8a0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OOkutZzmduEoM.09cK39MQ--~B/aD0xMzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c3251351433584be7e825803dfe4a8a0"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/brainstorm-cell-therapeutics-host-investor-120000320.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/brainstorm-cell-therapeutics-host-investor-120000320.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1989772923.USD","BK4516","LU1074936037.SGD","LU0006306889.USD","IE00BZ1G4Q59.USD","LU2089283258.USD","LU1162221912.USD","BK4585","LU1989772840.SGD","LU1363072403.SGD","BK4127","LENZ","LU0158827781.USD","BCLI","LU1548497426.USD","LU2271345857.HKD","LU0106261372.USD","KOL","BK4504","BK4139","LU1720051108.HKD","LU0225283273.USD","BK4181","LU0320765646.SGD","LU2111349929.HKD","LU0267386448.USD","BK4588","LU0158827948.USD","LU1668664300.SGD","LU2089284900.SGD","LU0098860793.USD","LU0971096721.USD","BK4218","LU2028103732.USD","LU0314104364.USD","LU2023251221.USD","BK4581","IE00BKVL7J92.USD","LU1720051017.SGD","BK4534","LU0106831901.USD","LU2357305700.SGD","HST"],"gpt_icon":0},{"id":"2488916515","title":"BRIEF-Brainstorm Strengthens Exosome Patent Portfolio, Receives Notice Of Allowance For U.S. Patent Covering Its Platform Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2488916515","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488916515?lang=en_us&edition=full_marsco","pubTime":"2024-12-03 20:07","pubTimestamp":1733227641,"startTime":"0","endTime":"0","summary":"Dec 3 (Reuters) - Brainstorm Cell Therapeutics   :   * BRAINSTORM: STRENGTHENS EXOSOME PATENT PORTFOLIO, RECEIVES NOTICE OF ALLOWANCE FOR U.S. PATENT COVERING ITS PLATFORM TECHNOLOGYSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCLI","BK4139"],"gpt_icon":0},{"id":"2488812919","title":"BrainStorm receives Notice of Allowance for patent on exosome technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2488812919","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488812919?lang=en_us&edition=full_marsco","pubTime":"2024-12-03 20:05","pubTimestamp":1733227537,"startTime":"0","endTime":"0","summary":"BrainStorm (BCLI) Cell Therapeutics announced that it has received Notice of Allowance from the U.S. Patent & Trademark Office for patent applicati...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/brainstorm-receives-notice-of-allowance-for-patent-on-exosome-technology?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/brainstorm-receives-notice-of-allowance-for-patent-on-exosome-technology?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCLI","BK4139"],"gpt_icon":0},{"id":"2488916373","title":"Brainstorm: Strengthens Exosome Patent Portfolio, Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2488916373","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488916373?lang=en_us&edition=full_marsco","pubTime":"2024-12-03 20:05","pubTimestamp":1733227504,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241203:nFWN3N31AK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCLI"],"gpt_icon":0},{"id":"2488367919","title":"BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2488367919","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488367919?lang=en_us&edition=full_marsco","pubTime":"2024-12-03 20:00","pubTimestamp":1733227200,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec. 3, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it has received Notice of Allowance from the U.S. Patent & Trademark Office  for patent application 16/981,757 which covers its proprietary exosome technology.\"This patent strengthens BrainStorm's intellectual property portfolio and highlights our commitment to advancing novel technologies for respiratory and neurodegenerative diseases,\" said Chaim Lebovits, BrainStorm's President and Chief Executive Officer. \"Our primary focus continues to be development of NurOwn for ALS as we prepare to initiate a Phase 3b registrational trial. We are seeking additional ways to unlock value from our assets and are pursuing strategic collaborations for the exosome platform.\". BrainStorm Cell Therapeutics Inc. is a leading developer of innovative therapies for debilitating neurodegenerative diseases, leveraging both autologo","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OOkutZzmduEoM.09cK39MQ--~B/aD0xMzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c3251351433584be7e825803dfe4a8a0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OOkutZzmduEoM.09cK39MQ--~B/aD0xMzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c3251351433584be7e825803dfe4a8a0"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/brainstorm-strengthens-exosome-patent-portfolio-120000643.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/brainstorm-strengthens-exosome-patent-portfolio-120000643.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2089284900.SGD","LU1989772923.USD","LU1162221912.USD","LU0158827948.USD","LU0314104364.USD","LU2271345857.HKD","LU1720051108.HKD","LU1363072403.SGD","IE00BKVL7J92.USD","LU1989772840.SGD","BCLI","IE00BZ1G4Q59.USD","LU1720051017.SGD","LU1668664300.SGD","BK4516","BK4585","BK4127","BK4581","LU0267386448.USD","LU0158827781.USD","LU0971096721.USD","LU0098860793.USD","LU0225283273.USD","LU0006306889.USD","LU2028103732.USD","BK4588","BK4139","LU0106261372.USD","LU0320765646.SGD","BK4534","LU2089283258.USD","LU0106831901.USD","BK4504","LU1074936037.SGD","LU2023251221.USD","LU2357305700.SGD","LU2111349929.HKD","LU1548497426.USD"],"gpt_icon":0},{"id":"2488968186","title":"BrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2488968186","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488968186?lang=en_us&edition=full_marsco","pubTime":"2024-12-02 20:00","pubTimestamp":1733140800,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec. 2, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will host a key opinion leader  webinar on Wednesday, December 11, 2024 at 10:00 AM ET. To register, click here.The webinar will feature Dr. Terry Heiman-Patterson, a KOL from the Lewis Katz School of Medicine at Temple University, who will discuss the current treatment landscape and advances for patients with amyotrophic lateral sclerosis . Dr. Heiman-Patterson will be joined by BrainStorm's management team, who will share updates on the company's planned Phase 3b registrational clinical trial, NurOwn, and future development plans.Successful completion of the randomized portion  of the Phase 3b trial is expected to support a Biologic License Application  for NurOwn.A live Q&A session will follow the formal presentations.BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adul","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OOkutZzmduEoM.09cK39MQ--~B/aD0xMzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c3251351433584be7e825803dfe4a8a0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OOkutZzmduEoM.09cK39MQ--~B/aD0xMzQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c3251351433584be7e825803dfe4a8a0"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/brainstorm-cell-therapeutics-host-kol-120000918.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/brainstorm-cell-therapeutics-host-kol-120000918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BCLI","KOL","BK4588","BK4218","BK4585","LENZ","HST","BK4181"],"gpt_icon":0},{"id":"2483337118","title":"Brainstorm Cell Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483337118","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483337118?lang=en_us&edition=full_marsco","pubTime":"2024-11-15 22:10","pubTimestamp":1731679844,"startTime":"0","endTime":"0","summary":"Brainstorm Cell Therapeutics Inc reports results for the quarter ended September 30 - Earnings SummaryBrainstorm Cell Therapeutics Inc BCLI.OQ reported a quarterly adjusted loss of 51 cents per share ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nL8N3MM1C6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCLI"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.brainstorm-cell.com","stockEarnings":[{"period":"1week","weight":-0.1736},{"period":"1month","weight":-0.2563},{"period":"3month","weight":-0.4758},{"period":"6month","weight":-0.4979},{"period":"1year","weight":-0.8928},{"period":"ytd","weight":-0.4758}],"compareEarnings":[{"period":"1week","weight":-0.0252},{"period":"1month","weight":-0.0559},{"period":"3month","weight":-0.0428},{"period":"6month","weight":-0.0121},{"period":"1year","weight":0.0743},{"period":"ytd","weight":-0.0428}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.001176},{"month":2,"riseRate":0.545455,"avgChangeRate":0.091643},{"month":3,"riseRate":0.636364,"avgChangeRate":0.073373},{"month":4,"riseRate":0.181818,"avgChangeRate":-0.072522},{"month":5,"riseRate":0.5,"avgChangeRate":0.093356},{"month":6,"riseRate":0.5,"avgChangeRate":-0.013366},{"month":7,"riseRate":0.7,"avgChangeRate":0.024805},{"month":8,"riseRate":0.1,"avgChangeRate":-0.02799},{"month":9,"riseRate":0.4,"avgChangeRate":-0.088205},{"month":10,"riseRate":0.2,"avgChangeRate":-0.142267},{"month":11,"riseRate":0.272727,"avgChangeRate":-0.013927},{"month":12,"riseRate":0.636364,"avgChangeRate":0.099729}],"exchange":"NASDAQ","name":"Brainstorm Cell Therapeutics","nameEN":"Brainstorm Cell Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Brainstorm Cell Therapeutics(BCLI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Brainstorm Cell Therapeutics(BCLI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Brainstorm Cell Therapeutics,BCLI,Brainstorm Cell Therapeutics股票,Brainstorm Cell Therapeutics股票老虎,Brainstorm Cell Therapeutics股票老虎国际,Brainstorm Cell Therapeutics行情,Brainstorm Cell Therapeutics股票行情,Brainstorm Cell Therapeutics股价,Brainstorm Cell Therapeutics股市,Brainstorm Cell Therapeutics股票价格,Brainstorm Cell Therapeutics股票交易,Brainstorm Cell Therapeutics股票购买,Brainstorm Cell Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Brainstorm Cell Therapeutics(BCLI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Brainstorm Cell Therapeutics(BCLI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction